Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
The study was terminated on May 12, 2011 due to poor enrollment prospects and the study's similarity to another ongoing trial with ReFacto AF.
The termination of this study has no impact on subject safety or well being. The decision to terminate the trial was not based on any safety concerns.
Age
12–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male patients 12 years of age and older.
Patients transitioned to Xyntha from other recombinant or plasma-derived FVIII replacement products.
Treatment history of 150 or greater exposure days to any FVIII products prior to Enrollment visit.
Negative inhibitor at screening or documentation of negative inhibitor titer within 6 weeks or less prior to study entry except for patients entering the study on immune tolerance induction therapy.
You may not be if
Bleeding disorder other than hemophilia A.
Inhibitor titer greater than or equal to 0.6 BU during screening except for patients on immune tolerance induction therapy.
Immunomodulatory therapy during screening period.
Known hypersensitivity to hamster protein.
Clareo Health | Study Evaluating The Safety Of Xyntha In Usual Care Settings
